```html

Quasi‑muscular Dystrophy (Facioscapulohumeral)

Overview

Facioscapulohumeral muscular dystrophy (FSHD), sometimes referred to in the literature as “quasi‑muscular dystrophy” because of its atypical progression, is one of the most common inherited muscular dystrophies. It primarily weakens the muscles of the face, shoulder blades, and upper arms, but can eventually involve the trunk and lower limbs.

• Prevalence: Approximately 1 in 20,000–25,000 people worldwide are affected, making FSHD the third‑most common hereditary muscular dystrophy after Duchenne and Becker types.<sup>Mayo Clinic</sup>
• Age of onset: Most individuals notice symptoms between ages 10 and 30, though 10‑15 % present after age 40.
• Gender: The disorder affects males and females equally.
• Genetics: FSHD is autosomal dominant; a single mutated copy of the gene is enough to cause disease. Two genetic sub‑types exist (FSHD‑1 & FSHD‑2) with slightly different mechanisms.

Symptoms

Symptoms can vary widely even among members of the same family. The classic pattern begins with facial and shoulder‑girdle weakness, followed by gradual spread to other muscle groups.

Facial muscles

• Smile weakness: Inability to fully elevate the corners of the mouth, giving a “smiling‑while‑crying” appearance.
• Eyebrow‑raising difficulty: Flattened eyebrows or limited upward movement.
• Whistling and blowing: Reduced force, making whistling, blowing out candles, or playing wind instruments challenging.

Shoulder‑scapular region

• Scapular winging: The shoulder blade protrudes backward, especially when pushing against a wall.
• Difficulty lifting arms above head: Early loss of shoulder abduction (raising arms sideways) and forward flexion.
• Upper arm weakness: Trouble with tasks such as combing hair or lifting light objects.

Trunk & lower limb involvement (later stage)

• Weakness of the abdominal muscles → “tight‑rope” gait, difficulty rising from a seated position.
• Hip flexor and knee extension weakness → stumbling, reduced stamina for walking or climbing stairs.
• Calf muscle atrophy (rare) → tip‑toe walking.

Other common features

• Asymmetry: One side may be more affected than the other.
• Muscle pain (myalgia): Often mild, worsened after activity.
• Fatigue: Disproportionate tiredness after exertion.
• Hearing loss: Reported in 5‑10 % of patients, especially high‑frequency loss.<sup>NIH</sup>
• Vision problems: Rarely, retinal vascular changes.

Causes and Risk Factors

Genetic mechanisms

• FSHD‑1 (≈95 % of cases): Deletion of one to ten repeat units (D4Z4) on chromosome 4q35. When the repeat count falls below 10, the DUX4 gene becomes inappropriately active in skeletal muscle, causing toxicity.<sup>CDC</sup>
• FSHD‑2 (≈5 %): No D4Z4 contraction, but mutations in epigenetic regulators (SMCHD1, DNMT3B) lead to DUX4 derepression.

Risk factors

• Family history: A first‑degree relative with FSHD confers a 50 % chance of inheritance.
• De novo mutations: Approximately 5‑10 % of cases arise spontaneously, usually when a parent carries a very short D4Z4 repeat that is not clinically evident.
• Sex chromosomes: The disease is linked to a specific “permissive” chromosome 4qA haplotype; presence of 4qB (non‑permissive) does not lead to disease even with a contraction.

Diagnosis

Because early symptoms can mimic other neuromuscular conditions, a systematic approach is essential.

Clinical evaluation

• Detailed family pedigree.
• Physical examination focusing on facial expression, scapular winging, and shoulder strength.
• Functional tests (e.g., Timed Up‑and‑Go, 6‑Minute Walk Test).

Electrodiagnostic studies

• Electromyography (EMG): Shows myopathic changes (short, polyphasic motor unit potentials) without nerve involvement.
• Nerve conduction studies: Typically normal, helping differentiate from neuropathies.

Imaging

• MRI of the shoulder girdle and thighs: Detects muscle fatty infiltration before clinical weakness becomes apparent.

Genetic testing

The definitive diagnosis is a molecular test for D4Z4 repeat size (southern blot or fiber‑FISH) and, if negative, sequencing of SMCHD1/DNMT3B.

Guidelines from the NIH recommend genetic confirmation for anyone with a suggestive phenotype.

Treatment Options

Currently there is no cure, but several interventions can slow progression, maintain function, and improve quality of life.

Medications

• Physical‑therapy‑guided stretching: Reduces contractures and maintains range of motion.
• Anti‑inflammatory agents: Low‑dose corticosteroids have modest benefit in selected patients, but long‑term side‑effects limit use.
• Experimental drugs: Trials of antisense oligonucleotides targeting DUX4 (e.g., losmapimod) are ongoing; patients may consider enrollment in clinical studies through ClinicalTrials.gov.

Procedures & devices

• Orthopedic surgery: Scapulothoracic fusion or pectoralis major transfer can stabilize the shoulder in severe winging.
• Assistive devices: Lightweight brace for the upper arm, custom‑fit orthoses for gait stability, and powered exoskeletons (experimental) to augment walking.

Lifestyle and supportive care

• Regular aerobic exercise (swimming, stationary cycling) within tolerance – improves cardiovascular health and mitigates fatigue.
• Strength training focusing on unaffected muscle groups (e.g., lower extremity, core) under physiotherapist supervision.
• Balanced diet rich in protein and omega‑3 fatty acids to support muscle metabolism.
• Vaccinations (influenza, pneumococcal) to prevent respiratory infections that could exacerbate weakness.

Living with Quasi‑muscular Dystrophy (Facioscapulohumeral)

Managing day‑to‑day life involves practical adaptations and emotional support.

Daily management tips

1. Plan your environment: Keep frequently used items at waist height to avoid overhead reaching.
2. Use ergonomic tools: Wide‑handle utensils, electric toothbrushes, and voice‑activated devices reduce strain on facial and shoulder muscles.
3. Stretch daily: Gentle neck, shoulder, and facial stretches (5‑10 minutes) prevent contractures.
4. Schedule rest periods: Adopt the “15‑minute rule” – work for 15 minutes, then rest for 2‑3 minutes to avoid cumulative fatigue.
5. Monitor hearing: Annual audiograms help detect early loss; hearing aids improve communication.
6. Stay socially connected: Join patient advocacy groups such as the FSHD Society for peer support and updates on research.

Psychosocial considerations

• Depression and anxiety rates are higher in chronic neuromuscular diseases; counseling or therapy should be offered.
• Occupational therapy can recommend workplace modifications (e.g., desk‑mounted keyboards) to maintain employment.

Prevention

Because FSHD is genetic, primary prevention is not possible. However, measures can reduce secondary complications:

• Genetic counseling for affected individuals planning families – discussion of prenatal testing or pre‑implantation genetic diagnosis.
• Early identification of weakness and prompt referral to physiotherapy to avoid secondary injuries.
• Vaccination and infection control to prevent respiratory crises.

Complications

If untreated or poorly managed, FSHD can lead to:

• Progressive loss of ambulation: Approximately 30 % of patients become reliant on a walker or wheelchair by age 50.
• Respiratory insufficiency: Weakness of intercostal muscles may cause reduced vital capacity; monitoring with spirometry is recommended.<sup>Cleveland Clinic</sup>
• Chronic pain: Muscle atrophy and joint degeneration can cause persistent discomfort.
• Psychological impact: Reduced independence may affect self‑esteem and lead to social isolation.
• Hearing loss & retinal changes: Though uncommon, they can affect communication and vision if unchecked.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, NIH Genetics Home Reference, Cleveland Clinic, WHO, peer‑reviewed articles from Neurology and Annals of Neurology. Always discuss personal health decisions with a qualified healthcare professional.

```